Evidence map›Paper›PMID 33796332›Full record

ReviewMultiple sclerosis journal - experimental, translational and clinical

Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy.

Lubna Almouzain, Fiona Stevenson, Declan Chard, Nur Abdul Rahman, Fiona Hamilton

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Lubna AlmouzainResearch Department at Primary Care and Population Health, Institution of Epidemiology, University College of London, London, UK.ORCID https://orcid.org/0000-0003-0920-4846
Fiona StevensonResearch Department at Primary Care and Population Health, Institution of Epidemiology, University College of London, London, UK.
Declan ChardDepartment of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.ORCID https://orcid.org/0000-0003-3076-2682
Nur Abdul RahmanResearch Department at Primary Care and Population Health, Institution of Epidemiology, University College of London, London, UK.
Fiona HamiltonResearch Department at Primary Care and Population Health, Institution of Epidemiology, University College of London, London, UK.
University College London · GBKing Saud University · SANational Hospital for Neurology and Neurosurgery · GBUniversiti Sains Islam Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe decision to have children can be complex, particularly for people with multiple sclerosis (MS). A key concern is the use of disease modifying drugs (DMDs) during pregnancy, and how continuing, stopping or switching them may affect the mother and child. In people with active MS, stopping medications puts the mother at risk of relapse and disease rebound.

objectivesReview evidence on the effect of different switching strategies in people with stable relapsing remitting MS (RRMS).

methodsWe searched MEDLINE, EMBASE, EMCARE, CINAHL, SCOPUS, Cochrane Library up to March 2020. Only papers in English were included and no other limits were applied. Seven articles were included: four cohorts, two case reports and one randomized controlled trial (RCT).

resultsTwo strategies were found: de-escalating, which was associated with an increased risk of relapses, and switching between first line injectables, with no change in relapse rate observed.

conclusionEvidence on the effect of switching strategy on disease course in stable RRMS patients planning for pregnancy is scarce, but when switching, current evidence suggests the risk of relapses mirrors known medication efficacy.

Indexed as

glatiramer acetateinterferonsMultiple sclerosisrelapsing-remittingsubstituteswitch

Identifiers

PMID33796332
PMCPMC7985951
OpenAlexW3139530103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.